MINNEAPOLIS, June 8, 2012 /PRNewswire/ -- Nonin Medical, Inc. announced today the U.S. market release of its EQUANOX™ Advance Model 8004CB Series neonatal/pediatric sensor. The EQUANOX Advance 8004CB Series Sensor with Nonin's patent-pending Dynamic Compensation™ algorithm is the first and only cerebral/somatic sensor to automatically account for pediatric brain-tissue-development variation when measuring oxygen saturation levels. The sensors are designed for use with Nonin's EQUANOX™ Advance Model 7600 Oximetry System in cerebral or somatic positions on patients weighing less than 40 kg.
EQUANOX is a near infra-red spectroscopy (NIRS)-based monitoring device that noninvasively and continuously detects oxygen saturation status in brain and other tissue. The device allows clinicians to quickly react to reverse harmful tissue ischemia events before they become critical.
"Nonin Medical is pleased to announce this latest advancement in tissue oxygen saturation monitoring for neonatal and pediatric patients," said Kevin McGowan, Vice President-Global Sales for Nonin Medical. "Until now, pediatric cerebral/somatic oximetry sensors have essentially been trimmed versions of adult sensors. Nonin's 8004CB Sensor is designed specifically for pediatric patients. The sensor features adhesive and non-adhesive versions for delicate skin, a small footprint for space-saving placement, short light-path spacing for pediatric-appropriate tissue-depth readings, and Nonin's Dynamic Compensation™ algorithm for calculating accurate, patient-specific values. And because the 8004CB provides a single-sensor solution for all patients less than 40 kg, it simplifies protocols and inventory requirements, saving time and money."
"Nonin's EQUANOX™ Advance 8004CB sensor represents a major step forward in